Physician profile
Manuel D Lopez
NPI 1942265533
$5,175.12
in general payments reported to CMS, 2019-2025
28 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $142 · 2021: $1,233 · 2022: $781 · 2023: $650 · 2024: $738 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550 · Education: $41.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.62 |
| Education | $41.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,145.23 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $763.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $360.76 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $297.80 | 2019-2025 | Vafseo |
| Allergan, INC. | $263.03 | 2020-2021 | |
| Genzyme Corporation | $248.94 | 2022-2023 | |
| Ardelyx, INC. | $222.01 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Vifor Pharma, INC. | $220.38 | 2021-2023 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $164.02 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $157.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $131.04 | 2025 | |
| Fresenius USA Marketing, INC. | $124.34 | 2021 | |
| Aurinia Pharma U.S., INC. | $121.60 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $119.14 | 2019 | |
| Medtronic, INC. | $114.24 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $102.75 | 2025 | Ozempic |
| Amgen INC. | $94.90 | 2022-2024 | Tavneos, Parsabiv, Aranesp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.25 | 2024-2025 | Jardiance |
| Kyowa Kirin, INC. | $73.38 | 2023-2025 | Crysvita |
| Mallinckrodt Hospital Products INC. | $69.97 | 2025 | Acthar |
| Calliditas Therapeutics US INC. | $62.76 | 2025 | Tarpeyo |
| Abbvie INC. | $60.38 | 2021 | |
| Cardiovascular Systems INC. | $50.71 | 2021 | |
| Scpharmaceuticals INC. | $44.50 | 2025 | |
| Glaxosmithkline, LLC. | $20.08 | 2022 | |
| Nxstage Medical, INC. | $17.92 | 2022 | |
| Pfizer INC. | $16.99 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.